+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Gastrointestinal Collaboration and Licensing Deals 2016-2023

  • Report

  • 200 Pages
  • October 2023
  • Region: Global
  • CurrentPartnering
  • ID: 2229054
Gastrointestinal Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the gastrointestinal deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of gastrointestinal deals from 2016 to 2023.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of gastrointestinal dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in gastrointestinal dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the gastrointestinal field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in gastrointestinal dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of gastrointestinal deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of gastrointestinal deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in gastrointestinal deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Gastrointestinal Collaboration and Licensing Deals provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse gastrointestinal collaboration and licensing deals
  • Benchmark analysis - identify market value of transactions
  • Financials terms - upfront, milestone, royalties
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

Report scope

Gastrointestinal Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of gastrointestinal trends and structure of deals entered into by leading biopharma companies worldwide.

Gastrointestinal Collaboration and Licensing Deals includes:

  • Trends in gastrointestinal dealmaking in the biopharma industry
  • Overview of collaboration and licensing deal structure
  • Directory of gastrointestinal deal records covering pharmaceutical and biotechnology
  • The leading gastrointestinal deals by value
  • Most active gastrointestinal licensing dealmakers

In Gastrointestinal Collaboration and Licensing Deals, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type
Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.

Gastrointestinal Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive SummaryChapter 1 - Introduction
Chapter 2 - Trends in gastrointestinal dealmaking
2.1. Introduction
2.2. Gastrointestinal partnering over the years
2.3. Gastrointestinal partnering by deal type
2.4. Gastrointestinal partnering by industry sector
2.5. Gastrointestinal partnering by stage of development
2.6. Gastrointestinal partnering by technology type
2.7. Gastrointestinal partnering by therapeutic indication
Chapter 3 - Financial deal terms for gastrointestinal partnering
3.1. Introduction
3.2. Disclosed financials terms for gastrointestinal partnering
3.3. Gastrointestinal partnering headline values
3.4. Gastrointestinal deal upfront payments
3.5. Gastrointestinal deal milestone payments
3.6. Gastrointestinal royalty rates
Chapter 4 - Leading gastrointestinal deals and dealmakers
4.1. Introduction
4.2. Most active in gastrointestinal partnering
4.3. List of most active dealmakers in gastrointestinal
4.4. Top gastrointestinal deals by value
Chapter 5 - Gastrointestinal contract document directory
5.1. Introduction
5.2. Gastrointestinal partnering deals where contract document available
Chapter 6 - Gastrointestinal dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by gastrointestinal therapeutic target
Deal Directory
Deal directory - Gastrointestinal deals by company A-Z 2016 to 2023
Deal directory - Gastrointestinal deals by technology type 2016 to 2023
Deal type definitions
Table of figures
Figure 1: Gastrointestinal partnering since 2016
Figure 2: Gastrointestinal partnering by deal type since 2016
Figure 3: Gastrointestinal partnering by industry sector since 2016
Figure 4: Gastrointestinal partnering by stage of development since 2016
Figure 5: Gastrointestinal partnering by technology type since 2016
Figure 6: Gastrointestinal partnering by indication since 2016
Figure 7: Gastrointestinal deals with a headline value
Figure 8: Gastrointestinal deals with upfront payment values
Figure 9: Gastrointestinal deals with milestone payment
Figure 10: Gastrointestinal deals with royalty rates
Figure 11: Active gastrointestinal dealmaking activity since 2016
Figure 12: Top gastrointestinal deals by value since 2016

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • 4D Pharma
  • 23andMe
  • AB-Biotics
  • AB Analitica
  • Abbvie
  • Ab E Discovery
  • Adacyte Therapeutics
  • ADL Bionatur Solutions
  • Advanced Medical German Company of Kuwait
  • Aerpio Therapeutics
  • Aevi Genomic Medicine
  • AIDS Clinical Trials Group
  • Akebia Therapeutics
  • Akeso Biopharma
  • Akkadeas Pharma
  • Alab
  • Albireo
  • Alfasigma
  • Alimentary Health
  • Allen Institute for Brain Science
  • Allergan
  • Alma Bio Therapeutics
  • Almirall
  • Alnylam Pharmaceuticals
  • Altos Group
  • Alvine Pharmaceuticals
  • Alvit LCS Pharma
  • Alvotech
  • Amarex Clinical Research
  • Ambu
  • Americas Hernia Society Quality Collaborative
  • Amgen
  • Amneal Pharmaceuticals
  • Amunix
  • Anatara Lifesciences
  • Angelini Pharma
  • ANI Pharmaceuticals
  • Anokion
  • Antibe Therapeutics
  • Apharm
  • Applied Molecular Transport
  • Arc Medical Design
  • Ardelyx
  • Aries Pharmaceuticals
  • Asana Medical
  • Ascension Health Ventures
  • AscentX Medical
  • Asklepion Pharmaceuticals
  • Assembly Biosciences
  • Astellas Pharma
  • AstraZeneca
  • Atlantic Healthcare
  • Atnahs Pharma
  • Aurobindo Pharma
  • Australasian Gastro Intestinal Research Foundation
  • Aziyo Biologics
  • Back-A-Line
  • Bausch Health Companies
  • Baxalta
  • Bayer Healthcare
  • Bazelet
  • B Braun
  • BC Children's Hospital
  • BDD Pharma
  • Beacon Discovery
  • Bestbion
  • Best Choice
  • Bill and Melinda Gates Foundation
  • Bio-Rad Laboratories
  • Biocodex Microbiota Foundation
  • BioDelivery Sciences
  • BioFire Diagnostics
  • Biofortis
  • Biogen
  • BIOgenetiX
  • Biohit
  • Biomecite Diagnostics
  • Biomedical Advanced Research and Development Authority
  • Biomedica Medizinprodukte
  • Biomerica
  • BiomX
  • Bioportugal Quimica Farmaceutica
  • BioRap Technologies
  • Biostage
  • BioStorage Technologies
  • BioSurfaces
  • Boehringer Ingelheim
  • Boston Pharmaceuticals
  • Bpifrance
  • Bridge Biotherapeutics
  • Bristol-Myers Squibb
  • Broad Institute
  • Buchang Pharmaceutical
  • Calypso Biotech
  • Camargo Pharmaceutical Services
  • Cambridge Clinical Laboratories
  • Cancer Prevention Pharmaceuticals
  • CannaKids
  • CapsoVision
  • Capsulomics
  • Carbiotix
  • Case Western Reserve University
  • Casper Pharma
  • CB2 Therapeutics
  • Cedars-Sinai Medical Center
  • Celgene
  • Celimmune
  • Cell Therapy Catapult
  • Celltrion
  • Celsius Therapeutics
  • Celtis Pharm
  • Centre Hospitalier Régional Universitaire (CHRU) de Lille
  • Cerevance
  • Certara
  • Charles River Laboratories
  • Cheplapharm Arzneimittel
  • Children's Hospital of Philadelphia
  • Chinese University of Hong Kong
  • CHU Sainte-Justine
  • Cilag AG
  • Cincinnati Children’s Hospital Medical Center
  • Cipher Pharmaceuticals
  • Cipla
  • CIRCA Scientific
  • CJ Corp
  • Cleveland Clinic
  • Clinigen
  • Codexis
  • Coherus Biosciences
  • Commonwealth Laboratories
  • Complix
  • Concordia Healthcare
  • Concordia Pharmaceuticals
  • Connecticut Children’s Medical Center
  • ConvaTec
  • Cook Biotech
  • Cook Medical
  • Cornell University
  • Cosmo Pharmaceuticals
  • COUR Pharmaceutical
  • Crohn's and Colitis Foundation of America
  • CRS Bio
  • Curant Health
  • CURE Pharmaceutical
  • Cyclerion Therapeutics
  • Daewoong Pharmaceutical
  • Daiichi Sankyo
  • DBV Technologies
  • Delphi Genetics
  • Diagnoplex
  • Diagnovus
  • Diversigen
  • Dongkook Pharmaceutical
  • Dr. Falk Pharma
  • Dr. Reddy's Laboratories
  • EA Pharma
  • ECM Therapeutics
  • Eisai
  • Eisai Inc
  • Elanco
  • Endo-Therapeutics
  • Endo International
  • EndoLogic
  • enGene
  • Engitix
  • Entellus Medical
  • Entera Health
  • Enterome Bioscience
  • Entrinsic Health Solutions
  • Epirus Biopharmaceuticals
  • EtectRx
  • Eunice Kennedy Shriver Institute of Child Health and Human Development
  • Eurobio
  • European Union
  • Eversana
  • Evoke Pharma
  • Evolve BioSystems
  • Evotec
  • Ewopharma
  • Exact Sciences
  • ExeGi Pharma
  • Faes Farma
  • Ferring Pharmaceuticals
  • Fiagon
  • Finch Therapeutics
  • Food and Drug Administration (FDA)
  • Food Marble Digestive Health
  • Fosun Pharmaceutical
  • Foundation for Celiac Disease Outcome Measures
  • Frazier Healthcare Ventures
  • French National Institute for Agricultural Research
  • Fresenius Kabi Pharmaceuticals
  • Fresenius Medical Care
  • FSC Laboratories
  • FSC Pediatrics
  • FSD Pharma
  • Fujifilm
  • Fujifilm Kyowa Kirin Biologics
  • G-Tech Medical
  • Galapagos
  • Galena Biopharma
  • Gemelli Biotech
  • Genentech
  • Genetic Analysis
  • Genten Therapeutics
  • Georgia State University
  • Gilead Sciences
  • Giraffes Pharmaceutical
  • GlaxoSmithKline
  • Glenmark Pharmaceuticals
  • Global Centers for Therapeutic Innovation
  • Gossamer Bio
  • Great Belief International
  • Great Ormond Street Hospital (GOSH)
  • Grunenthal
  • Grupo Ferrer
  • Hadasit Bioholdings
  • Hadasit Medical Research Services and Development
  • Harvard Apparatus Regenerative Technology
  • Harvest Capital Strategies
  • Healthcare Royalty Partners
  • HealthTrust
  • Helsinn Healthcare
  • Henry Schein
  • HiFiBio
  • Highland Therapeutics
  • Hollister-Stier Labs
  • Holobiome
  • Horizon 2020
  • Humabs BioMed
  • Icahn School of Medicine at Mount Sinai
  • Idera Pharmaceuticals
  • IMIDomics
  • Immune Pharmaceuticals
  • ImmuNext
  • Immunic
  • ImmunogenX
  • Impax Laboratories
  • Imperial College London
  • Inception Sciences
  • InDex Pharmaceuticals
  • Indiana Biosciences Research Institute
  • Infirst HEALTHCARE
  • INNOVAMEDICA
  • Innovate Biopharmaceuticals
  • Innovation Pharmaceuticals
  • InQpharm
  • Insightra Medical
  • Institut Gustave Roussy
  • Instituto de Ciencias Farmaceuticas
  • Intract Pharma
  • Intralytix
  • Intrexon
  • IntroMedic
  • Ionis Pharmaceuticals
  • Ipsen
  • Ironwood Pharmaceuticals
  • ISA Scientific
  • Jaguar Health
  • Jamieson
  • Janssen Biotech
  • Janssen Pharmaceuticals
  • Janssen Pharmaceutica NV
  • Janssen Research & Development
  • Janssen Sciences
  • Jitsubo
  • Johns Hopkins University
  • Johnson & Johnson Consumer Companies
  • Johnson & Johnson Innovation
  • JSR
  • Juntendo University
  • Juventas Therapeutics
  • Kanyos
  • Karolinska Institute
  • Karo Pharma
  • Keio Gijuku University
  • Kennedy Trust For Rheumatology Research
  • Kenneth Rainin Foundation (KRF)
  • KineMed
  • Kings College London
  • Knight Therapeutics
  • Korea Pharma
  • Kwang Dong Pharmaceutical
  • Kyowa Hakko Kirin
  • Laboratories Acbel
  • Laboratorio Daudt
  • Laboratorios Bago
  • Lead Pharma
  • Leona M and Harry B Helmsley Charitable Trust
  • LEO Pharma
  • Les Laboratoires Servier
  • Lipid Therapeutics
  • LiveLeaf
  • LNC
  • Lonza
  • Lucid Diagnostics
  • Luminex
  • Lycera
  • Magellan Health Services
  • Magnet Sales and Manufacturing
  • Massachusetts General Hospital
  • Mauna Kea Technologies
  • Mayo Clinic
  • McMaster University
  • McNeil Consumer Pharmaceuticals
  • Medgenics
  • MediBeacon
  • Medical University of Graz
  • MediGene
  • Medigus
  • Medimetrics
  • MedImmune
  • Merit Medical Systems
  • Mesoblast
  • Metabiomics
  • Metagenics
  • Microbiotica
  • Microline Surgical
  • Midatech
  • MiTest Health
  • Mitsubishi Tanabe Pharma
  • Mobidiag
  • Molteni Farmaceutici
  • Momenta Pharmaceuticals
  • Monash University
  • Morphic Therapeutic
  • Mor Research Applications
  • Mundipharma
  • Mylan Laboratories
  • Mylan Pharmaceuticals
  • Naia Pharma
  • Nanjing Micro-Tech
  • National Heart
  • Lung and Blood Institute
  • National Institute of Allergy and Infectious Diseases
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Institutes of Health
  • Naval Medical Research Center
  • Nektar Therapeutics
  • Neoteryx
  • Nestle Health Science
  • NeuTec Pharma
  • Nexus Medical
  • Ninepoint Medical
  • Nodality
  • Nogra Pharma
  • Norgine
  • Northwestern University
  • North Zealand University Hospital
  • NovaMedica
  • Novartis
  • Novartis Institute for Tropical Diseases
  • Noventure
  • Novigenix
  • NovImmune
  • Novo Nordisk
  • NuBiyota
  • Numab
  • NuMedii
  • Numerate
  • Nutriband
  • Nutricion
  • Olympus
  • Olympus Medical Systems
  • Omega Pharma
  • Onegevity
  • Origin Biosciences
  • OSE Immunotherapeutics
  • Otsuka
  • Otsuka America Pharmaceutical
  • Owlstone Medical
  • PACA Inovation
  • Palobiofarma
  • Panaxia
  • PanTheryx
  • Paragon Bioservices
  • ParaPRO
  • Parexel
  • Parvus Therapeutics
  • Patheon
  • PAVmed
  • PEAR Therapeutics
  • Pendopharm
  • Pentax
  • Perelman School of Medicine
  • PerkinElmer
  • Perrigo
  • Pfizer
  • PharmaCare Management
  • PharmaSwiss
  • Phathom Pharmaceuticals
  • Pierre Fabre
  • PlantEXT
  • Pliant Therapeutics
  • Polpharma
  • Portal Instruments
  • Prana Biotechnology
  • PredictImmune
  • Premier Inc
  • Prescient Medical
  • Probi
  • Progenity
  • Progressive Medical International
  • Progressive Spinal Technologies
  • Prometheus Laboratories
  • Pronutria
  • Protagonist Therapeutics
  • Provention Bio
  • Proxy Biomedical
  • Purdue Pharma
  • PureTech Health
  • PvP Biologics
  • Qualicaps
  • Qu Biologics
  • Queen Mary University of London
  • Quest Diagnostics
  • Quotient Clinical
  • R-Tech Ueno
  • Rafa Pharmaceuticals
  • ReadSense Genomic Center
  • Rebiotix
  • Reckitt Benckiser
  • Recordati
  • RedHill Biopharma
  • Regentys
  • Renexxion
  • Repligen
  • ResearchMatch
  • Retrophin
  • Revive Pharmaceuticals
  • Rising Pharmaceuticals
  • Ritter Pharmaceuticals
  • Roche
  • Romark Laboratories
  • Royal Free Hospital
  • Salix Pharmaceuticals
  • Samsung Bioepis
  • Sandoz
  • Sanofi
  • SciCann Therapeutics
  • Scripps Research Institute
  • Second Genome
  • Seed Mena
  • Selexis
  • Sequana Medical
  • Seres Therapeutics
  • Shandong Luoxin Pharma
  • Shionogi
  • Shire Pharmaceuticals
  • Signum Surgical
  • Simulations Plus
  • Sinovant Sciences
  • Sloan Pharma
  • Smart Medical Systems
  • Soligenix
  • SomaLogic
  • SonarMD
  • Sosei Heptares
  • SpectraScience
  • Strand Life Sciences
  • Stratis Medical
  • Structural Genomics Consortium
  • Sucampo Pharmaceuticals
  • Sutter Health
  • Swedish Orphan Biovitrum
  • Swixx Biopharma
  • Symbiotix Biotherapies
  • Synergy Pharmaceuticals
  • Synlab
  • Synlogic
  • Synthetic Biologics
  • Taewoong Medical
  • Takeda Pharmaceutical
  • TARGET PharmaSolutions
  • Teligent
  • Tetra Bio-Pharma
  • The Cell and Gene Therapy Unit
  • The Crohn's and Colitis Foundation of Canada
  • The HUB Foundation
  • Theradiag
  • Theranostica
  • Theravance
  • Theravance Biopharma
  • The Vancouver Island Health Authority
  • Thiel Foundation
  • Thorne Research
  • Tianyin Pharmaceutical
  • TiGenix
  • Tillotts Pharma
  • Tissium
  • Tiziana Life Sciences
  • TransEnterix
  • Trizell
  • TxCell
  • UCB
  • Unilabs
  • UniQuest
  • Universite catholique de Louvain
  • University College Cork
  • University College London
  • University of Adelaide
  • University of Birmingham
  • University of British Columbia
  • University of Calgary
  • University of California
  • San Diego
  • University of California Los Angeles
  • University of California San Francisco
  • University of Manitoba
  • University of Maryland Ventures
  • University of Massachusetts
  • University of North Carolina
  • University of Pennsylvania
  • University of Pittsburgh
  • University of Sherbrooke
  • University of Tokyo
  • University of Washington
  • University of Windsor
  • Utrecht University
  • Valbiotis
  • Vcell Healthcare
  • V ClinBio
  • Vedanta Biosciences
  • Vedco
  • Verily
  • Vertex Pharmaceuticals
  • Via Surgical
  • Vinnova
  • Virginia Catalyst
  • Vital Food Processors
  • Vital Therapies
  • Vivelix Pharmaceuticals
  • Vizient
  • Washington University in St Louis
  • Weill Cornell Medical College
  • Wockhardt
  • WuXi Biologics
  • Xoma
  • Yale University
  • Yissum Research Development
  • Zealand Pharma

Methodology

  • The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
  • The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
  • The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
  • The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
  • The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

The publisher provides comprehensive coverage of the following partnering or deal types:

  • Asset purchase
  • Assignment
  • Co-development
  • Co-market
  • Co-promotion
  • Collaborative R&D
  • Contract service
  • CRADA
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Loan
  • Manufacturing
  • Marketing
  • Option
  • Promotion
  • Research
  • Royalty financing
  • Settlement
  • Spin out
  • Sub license
  • Supply
  • Termination
  • Warrant

Every deal record is fully categorized and includes the following data, where available:

  • Industry sector
  • Therapy areas
  • Technology type
  • Deal components
  • Financial terms
  • Stage of development
  • Exclusivity
  • Asset type
  • Geographic focus
  • Excluded geography
  • Company press release
  • SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

 

 

Loading
LOADING...